Substance / Medication

Pirenzepine

Overview

Active Ingredient
pirenzepine
RxNorm CUI
8352

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Effects of pirenzepine on vonoprazan-induced gastric acid inhibition and hypergastrinemia.
Suzuki Takahiro, Higuchi Tomohiro, Kagami Takuma et al. · Eur J Clin Pharmacol · 2021
PMID: 34059932RCT
Effects of pirenzepine on Dai-kenchu-to-induced elevation of the plasma neuropeptide levels in humans.
Sato Yuhki, Inoue Shin, Katagiri Fumihiko et al. · Biol Pharm Bull · 2006
PMID: 16394532Trial
Reduction of clozapine-induced hypersalivation by pirenzepine is safe.
Schneider B, Weigmann H, Hiemke C et al. · Pharmacopsychiatry · 2004
PMID: 15048609Trial
Safety and efficacy of 2% pirenzepine ophthalmic gel in children with myopia: a 1-year, multicenter, double-masked, placebo-controlled parallel study.
Siatkowski R Michael, Cotter Susan, Miller Joseph M et al. · Arch Ophthalmol · 2004
PMID: 15534128Trial
Effect of 2-week treatment with pirenzepine on fasting and postprandial glucose concentrations in individuals with type 2 diabetes.
Issa Basil G, Davies Nichola, Hood Kerenza et al. · Diabetes Care · 2003
PMID: 12716837Trial
A tolerability study of pirenzepine ophthalmic gel in myopic children.
Bartlett Jimmy D, Niemann Katherine, Houde Barbara et al. · J Ocul Pharmacol Ther · 2003
PMID: 12828845Trial
Human cardiac beta1- or beta2-adrenergic receptor stimulation and the negative chronotropic effect of low-dose pirenzepine.
Jakubetz J, Schmuck S, Wochatz G et al. · Clin Pharmacol Ther · 2000
PMID: 10824634Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pirenzepine (substance)
SNOMED CT
398669004
UMLS CUI
C0031978
RxNorm CUI
8352

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.